电邮这篇文章 Role of eosinophil granulocytes in the occurrence of restenosis in patients after coronary stenting with drug-eluting stents
- 作者: Gabbasov ZA1, Kozlov SG1, Imaeva AÉ1, Saburova OS1, Masenko VP1
-
隶属关系:
- ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
- 期: 卷 86, 编号 9 (2014)
- 页面: 90-96
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31579
- ID: 31579
如何引用文章
全文:
详细
AIM. To study the role of eosinophil granulocytes in the development of restenosis after drug-eluting stent (DES) implantation. MATERIALS AND METHODS. The blood levels of eosinophils, eosinophil cationic protein (ECP), immunoglobulin E (IgE), and C-reactive protein (CRP) were compared in 170 patients with coronary heart disease (CHD) and stable angina who had undergone recoronarography within the first year after endovascular myocardial revascularization using DES. The blood level of eosinophils was determined by the results obtained employing the FACS Calibur flow cytofluorometer (Becton Dickinson, USA). That of ECP, IgE, and CRP was estimated by enzyme immunoassay by means of an Immulite-100 analyzer (Siemens, Germany). The data were presented as median (25th percentile and 75th percentile). RESULTS. The blood eosinophil level was 272 (234; 292) cells/µl in patients with restenosis while that was 134 (85; 156) cells/µl in those without restenosis (p=0.002). The plasma ECP level proved to be greater in the patients who had developed restenosis after DES implantation than in those who had not [17.7 (11.2; 24) and 9 (6.4; 12.9) ng/ml, respectively (p=0.017). At 6 months after DES implantation, the level of ECP was significantly higher (8.6 (7.3; 9.7) ng/ml) than the baseline level (p=0.04). Later on, there was an even greater increase in ECP levels. No significant changes were noted in blood ECP levels after bare stent implantation. CONCLUSION. The findings suggest that there is a relationship between the occurrence of restenosis and the enhanced activity of eosinophil granulocytes in CHD patents after DES implantation.
作者简介
Z Gabbasov
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
Email: zufargabbasov@yandex.ru
S Kozlov
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
A Imaeva
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
O Saburova
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
V Masenko
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России
参考
- Ferrante G., Niccoli G., Biasucci L.M. et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 2008; 9 (3): 156-165.
- Inoue T., Croce K., Morooka T. et al. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011; 4 (10): 1057-1066.
- Costa M.A., Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111 (17): 2257-2273.
- Curcio A., Torella D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011; 75 (6): 1287-1296.
- Shoji M., Koba S., Kobayashi Y. Roles of Bone-Marrow-Derived Cells and Inflammatory Cytokines in Neointimal Hyperplasia after Vascular Injury. Biomed Res Int 2014; 2014: 945127.
- Finn A.V., Kolodgie F.D., Harnek J. et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112 (2): 270-278.
- Niccoli G., Montone R.A., Ferrante G., Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010; 56 (22): 1783-1793.
- Hao H., Ishibashi-Ueda H., Tsujimoto M. et al. Drug-eluting stent: importance of clinico-pathological correlations. Circ J 2011; 75 (7): 1548-1558.
- Toor I.S., Jaumdally R., Lip G.Y. et al. Eosinophil count predicts mortality following percutaneous coronary intervention. Thromb Res 2012; 130 (4): 607-611.
- Weil G.J., Chused T.M. Eosinophil autofluorescence and its use in isolation and analysis of human eosinophils using flow microfluorometry. Blood 1981; 57 (6): 1099-1104.
- Thurau A.M., Schylz U., Wolf V. et al. Identification of eosinophils by flow cytometry. Cytometry 1996; 23 (2): 150-158.
- Virmani R., Guagliumi G., Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109 (6): 701-705.
- Finn A.V., Nakazawa G., Joner M. et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27 (7): 1500-1510.
- Kawano H., Koide Y., Baba T. et al. Granulation tissue with eosinophil infiltration in the restenotic lesion after coronary stent implantation. Circ J 2004; 68 (7): 722-723.
- Kornowski R., Hong M.K., Tio F.O. et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31 (1): 224-230.
- Muniz V.S., Weller P.F., Neves J.S. Eosinophil crystalloid granules: structure, function, and beyond. J Leukoc Biol 2012; 92 (2): 281-288.
- Niccoli G., Schiavino D., Belloni F. et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. Eur Heart J 2009; 30 (11): 1340-1347.
补充文件
